PDX-Derived Prostate Cancer Organoid Model

Almost all progressive prostate cancers can be repressed by androgen deprivation therapy, but they frequently recur in the form of castrate-resistant prostate cancer (CRPC). Therefore, the treatment of this disease is quite complex. Due to genomic heterogeneity in vivo, it is urgent to develop a reliable in vitro model that faithfully reflects the genetic and phenotype features of prostate cancer. Based on rich experience in drug development, Creative Biolabs has successfully established 3D organoid models such as PDX-derived prostate cancer organoid model to accelerate the progress of your projects.

Shortcomings of Common Models

Cell lines are one of the mainstream models in the field of tumor investigation. But for prostate cancer, available cell lines are relatively limited. Moreover, their applications are hindered because of the inability to reflect the diversity of tumors and precisely predict in vivo treatment responses. In genetically engineered mouse models (GEMMs) and patient-derived xenografts (PDXs), there are also drawbacks. For example, GEMMs fail to generally represent clinical CRPC and PDXs have obvious limitations in high-throughput screening, genetic manipulation, and mechanism study.

Advantages of PDX-derived Prostate Cancer Organoid Models

In prostate cancer, PDX-derived organoids (PDXOs) are generated from the PDX tissue. As a novel model, they combine the strengths of both PDXs and organoids and present a close clinical correlation. Overall, the advantages of prostate cancer PDXOs can be summarized as follows.

• They recapitulate tissue structure and phenotypic features of the original tumor.
• The ex vivo models capture the genomic characteristics and retain subclonal diversity.
• Such models are initially proliferative, so they are very appreciated for various in vitro manipulations, such as high throughput, biochemical assays, and mechanistic analysis.
• The experimental flexibility exists in prostate cancer PDXOs and guarantees the feasibility of genetic manipulations in vitro.The PDX-derived models can be used to construct organoid-derived xenografts (ODXs) in return.

Applications

At present, the prostate cancer PDXO model is still in its infancy and the related research is limited. But the current data have pointed to its translational potential as a robust preclinical model for drug screening. This organoid technology is considered groundbreaking and is of profound significance for further prostate cancer research.

Fig.1 Applications of PDX-derived prostate cancer organoid models. (Creative Biolabs)

Related Services

As a reputable biology company, Creative Biolabs has extended its business to 3D biology and will continuously explore some new areas. With rich expert resources and a professional research team, we have successfully constructed an ex vivo physiological model network including 3D organoid models for various tumor research. Like always, we are devoted to providing high-quality PDX-derived prostate cancer organoid models and related technology services listed below to promote human health. Please contact us in time to obtain more information for any support you want.

Related Sections:

• Patient-Derived Organoid (PDO) Model
• PDX-Derived Organoid (PDXO) Tumor Model